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Chondrosarcoma (CHS) is a malignant cartilage-forming tumor and usually occurs within the medullary canal of long bones
and pelvic bones. Based on the morphologic feature alone, a correct diangosis of CHS may be diﬃcult, Therefore, correlation of
radiological and clinicopathological features is mandatory in the diagnosis of CHS. The prognosis of CHS is closely related to
histologic grading, however, histologic grading may be subjective with high inter-observer variability. In this paper, we present
histologic grading system and clinicopathological and radiological ﬁndings of conventional CHS. Subtypes of CHSs, such as
dediﬀerentiated, mesenchymal, and clear cell CHSs are also presented. In addition, we introduce updated cytogenetic and
molecular genetic ﬁndings to expand our understanding of CHS biology. New markers of cell diﬀerentiation, proliferation, and
cell signaling might oﬀer important therapeutic and prognostic information in near future.
1.Introduction
Chondrosarcoma (CHS) is a rare malignant tumor that
produces cartilage matrix. The estimated overall incidence of
CHSs is 1 in 200,000 per year [1], and it is the third most
frequent malignant bone tumor after multiple myeloma
and osteosarcoma. It is estimated that CHSs account for
approximately 3.6% of the annual incidence of all primary
bone malignancies in the USA [2]a n d2 0 ∼30% of primary
malignant bone tumors [3].
CHSs that arise de novo are called primary CHSs,
whereas CHSs developing superimposed on preexisting
benign cartilage tumors such as an enchondroma or osteo-
chondroma are referred to as secondary CHSs. CHSs are
a heterogeneous group of tumors that can be categorized
by anatomic location as central when they occur within
the medullary canal or peripheral when they occur in the
cartilage cap of an exostosis. In addition to conventional
CHSs that show hyaline cartilage diﬀerentiation, there are
other types of CHSs such as dediﬀerentiated, mesenchymal,
or clear cell subtypes which show distinct genetic and
clinicopathologiccharacteristics[4](T ables1and2).Myxoid
CHS is not included in this paper because its existence in
bone is highly controversial.
Most (about 85%) of CHSs, however, are of conventional
CHSs, and the majority arises in the medullary cavity of long
bone. The minority (up to 15%) of conventional CHSs is
secondary peripheral CHSs which develop from the surface
of bone as a result of malignant transformation within the
cartilage cap of a preexisting benign cartilage tumor such as
osteochondroma or develop de novo on the bone surface,
and these are not uncommonly referred as juxtacortical or
periosteal CHSs.
2.ConventionalIntramedullaryCHSs
2.1. Epidemiology. Conventional CHS of bone is the most
commontypeofprimaryCHS.PrimaryCHStypicallyaﬀects
an old population. The majority of patients are older than 50
years. The peak incidence is in the ﬁfth to seventh decades of
life. There is a male predilection of 1.5–2 to 1 [1].
2.2. Sites of Involvement. CHS can involve any bone; the
incidence of axial and appendicular involvement is very
similar. The bones of the pelvis, especially for ilium, are fre-
quently involved. Long tubular bones are frequently aﬀected.
The proximal femur is the most preferred site, followed
in frequency by proximal humerus, distal femur, and ribs.2 Sarcoma
Other less frequently involved bones are the spine, scapula,
and sternum. CHS rarely involves craniofacial bones, neck,
forearm,clavicle,andsesamoids(includingthepatella).CHS
in the small tubular bones is extremely rare (1∼4% of all
cases) [3, 5, 6].
2.3. Clinical Features and Imaging. Clinical symptoms are
mostly nonspeciﬁc. Localized pain is the most frequent
presenting symptom (about 80%) after local swelling. The
symptoms are usually insidious, progressive, and worse at
night and have a long duration (several months or years).
Pathologic fractures are also common at initial presentation
(up to 27%).
Radiographs of conventional CHS typically reveal a
mixed lytic and sclerotic pattern with characteristic small
calciﬁcations, often referred as “popcorn” or “ringlets” calci-
ﬁcations. In the long bones, primary CHS most commonly
involves the metaphysis (49%), followed by the diaphysis
(36%) (Figure 1). The presence of typical calciﬁcations is
radiologically diagnostic of cartilage, but often does not
discriminate between benign, borderline, or malignant types
of lesions. Size of the lesions (<5cm), lack of break through
the cortex, lack of inﬁltrative pattern, and lack of lytic
component favors a benign or borderline process, while
location in the axial skeleton and size greater than 5cm
are reliable predictor of low-grade CHS [7]. Radiographic
ﬁndings including cortical destruction, soft tissue extension,
andpermeativechangessuchasthe“moth-eatenpattern”are
commonly associated to malignancy. A permeative pattern
is often seen with high-grade CHS. Endosteal scalloping
is a sign of aggressiveness in intramedullary cartilaginous
lesions, but it is not completely diagnostic of malignancy.
According to Murphey et al. [3], endosteal scalloping greater
than two-thirds of the normal thickness of the long bone
cortex is strong evidence of CHS over enchondroma. Thus,
enchondromasandintramedullarylow-gradeCHSs(border-
line tumors) of long bones often share similar radiological
features. These lesions should be diagnosed by histologic
examination after a complete resection of the lesion is made
whether it is an excision or a complete curettage. Magnetic
resonance (MR) imaging is also a preferred modality in
diagnosis of cartilaginous tumor as well as in evaluation of
the extent of marrow involvement and presence of soft tissue
extension. On T1-weighted images after gadolinium contrast
injection, marked “septal” or “ring-and-arc” enhancement
is typical for enchondromas and low-grade CHSs which
corresponds to ﬁbrous bands between the conﬂuent carti-
lage lobules on the histologic analysis. Inhomogeneous or
homogeneous enhancement of high-grade CHSs correlates
with high cellular areas on the microscopic examination [8].
In addition, fast contrast-enhanced MR imaging could assist
in diﬀerentiation between enchondromas and CHSs. In the
adult patient, both early and exponential enhancement is
predictors of CHSs [9].
2.4. Pathology. Conventional intramedullary CHSs are large
lesions, usually greater than 4cm in size [3]. CHSs grow
in a lobulated pattern and are usually ﬁrm but may be
Table 1: Classiﬁcation of CHSs.
Anatomic classiﬁcation
Intramedullary (central)
Peripheral
Juxtacortical (periosteal)
Primary versus secondary
Primary
A r i s ed en o v o
Secondary
Arise in a benign precursor, either an osteochondroma or
enchondroma
Arise in a benign precursor, either an
osteochondromatosis or enchondromatosis
Histologic classiﬁcation
Conventional
Dediﬀerentiated
Mesenchymal
Clear cell
soft, mucoid, or even gelatinous (Figure 2). They are white
or bluish gray and often focally gritty because of matrix
calciﬁcations. The presence of gray hemorrhagic ﬁsh ﬂeshy
tissue or myxoid change is not uncommonly associated to a
high-grade lesion. Histologic examination reveals lobules of
hyaline cartilage with variable degrees of cellularity, myxoid
change, and calciﬁcation. The chondrocytes usually have
enlarged, hyperchromatic nuclei with binucleation (Figures
3(a)–3(c)). Necrosis and mitoses are mostly seen in high-
grade lesions.
2.4.1. Grading. The grading is primarily based on nuclear
size, hyperchromasia, cellularity, and mitoses [10]. The
nuclear size is evaluated by assessing the tumor cells whether
those cells are small and dark staining, moderate sized with
visible intranuclear detail, or large and pleomorphic. The
background is considered chondroid if deﬁnite lacunae are
observed and myxoid if the cells are separated by basophilic
intercellular substance without deﬁnite lacunae.
Grade 1 (low-grade) lesions are poorly cellular with
hyperchromatic round nuclei the size of a mature lympho-
cyte. There are no mitotic ﬁgures, or nuclear atypia and the
cells retain the lacunar pattern. Myxoid background is not
present, but there may be some degenerative myxoid change.
Binucleated cells are rare if any. Dense cellularity, presence
of signiﬁcant numbers of moderately sized or larger nuclei,
and mitotic ﬁgures are not features of low-grade CHS and,
if present, indicate a higher grade of CHS [10]. Grade 2
(intermediate)tumorsaremorecellularlesionscharacterized
by cells with nuclear enlargement; the chromatin may be
ﬁne with presence of nucleoli, and mitotic activity is rarely
present. The cells also retain the lacunar pattern, and there
is no myxoid change, although degenerative myxoid may
be present. When myxoid stroma appears, this is clue that
the tumor may become aggressive or is frankly malignantSarcoma 3
Table 2: Summary of frequency, age, sex, and prognosis of CHSs.
Subtype Frequency Gender (M:F) Peak age 5-year survival
Conventional 85% 1.5–2:1 40–60 G1:89%, G2, and G3:57%
Periosteal <2% Slight male predilection 20–30 83%
Dediﬀerentiated 10% 1:1 50–60 <10%
Mesenchymal <2–13% 1:1 10–20 54.6%
Clear cell 1-2% 2.6:1 20–30 >80%
Figure 1: A well-demarcated cartilaginous tumor, measuring
6.5cm in greatest dimension, in the metaphysis of distal femur. The
mass extends through the periosteum to adjacent soft tissue.
especially if it is associated to mitotic activity. Grade 3 (high-
grade) tumors characteristically display 2 or more mitoses
per ten high-power ﬁelds in the most cellular areas. There
is usually a myxoid background associated to spindle or
pleomorphic cells and the lacunar pattern is predominantly
lost. Foci of necrosis are usually seen. For the purpose of
clariﬁcation, myxoid change may associate to malignancy
in cartilage tumors or may be degenerative; the latter is
characterized by the presence of myxoid areas without
cellularity,whilethemyxoidchangeassociatedtomalignancy
is characterized by a tumor without lacunar pattern with
atypical spindle or stellate cells ﬂoating in a myxoid stroma
(Figures 4(a)–4(d) and 5)[ 1, 3].
2.4.2. Diﬀerential Diagnosis. More than 90% of conventional
CHSs are low- to intermediate-grade tumors and should
be distinguished from enchondroma. Permeation of cortical
bone and/or preexisting medullary bone is most important
to distinguish CHSs from enchondromas [11], for which it
is crucial to take biopsy material consisting of cortical and
medullary bones, and one should observe the growth pattern
(Figure 6). One should avoid misinterpreting enchondroma
as CHS by regarding areas of cartilage crushed into sur-
rounding marrow spaces as true permeation in curettage
Figure 2: An intramedullary cartilaginous mass, measuring 9.5cm
ingreatestdimension,inthemetadiaphysisofproximalfemur.Note
the white to bluish gray and lobulated cut surface and cortical
destruction.
specimen. The frequency of cellularity, double nuclei, and
mitoses is similar between enchondroma and low-grade
CHS. Recent study suggests that presence of myxoid matrix
≥20% and/or host bone entrapment strongly suggests CHS
[12]. Extensive myxoid change is an ominous sign in a
chondroid lesion, and in such cases one should try to search
for other histologic features suggesting CHS (Figure 7). If
one sees areas with undoubtful neoplastic osteoid, the lesion
should be considered osteosarcoma with chondroblastic
diﬀerentiation.
2.5. Genetics. S of a r ,s e v e r a la t t e m p t sh a v eb e e nm a d et o
identify reliable molecular markers and therapeutic targets
for CHS [13]. Collagen subtype has been proposed to reﬂect
diﬀerentiation of CHS, speciﬁcally collagen types II and X
as well as the proteoglycan aggrecan as a marker for mature
neoplastic phenotype and collagen type I as a marker rep-
resenting proliferative, “dediﬀerentiated” phenotype [14].
Cyclooxygenase-2 overexpression was also proposed as a
marker associated with histologic grade and poor survival
[15]. However, none of these biologic markers has been
proved to provide independent prognostic information. The
attempt to assess the eﬀect of celecoxib (Celebrex) on
CHS growth using xenograft model did fail to attain a4 Sarcoma
(a)
(b)
(c)
Figure 3: (a) Atypical chondrocytes with binucleation and
eosinophilic cytoplasm; (b) chondrosarcoma with myxoid change;
(c) chondrosarcoma with necrotic tumor cells and calciﬁcation.
satisfactory result [16]. Hedgehog signaling pathway that is
important for development of central CHS is a potential
therapeutic target and has been under preclinical tests
[17]. Of the Indian hedgehog (IHH)/parathyroid hormone-
related protein (PTHLH) pathway, induction of the PTHLH
pathway and reactivation of bcl2 have been implicated in
pathogenesis and progression of conventional CHS, and bcl2
was suggested to be a reliable marker for the distinction
between low-grade CHS and enchondromas [18].
T h e r ei si n c r e a s eo fg e n e t i ca b e r r a t i o n sa sC H S sp r o g r e s s
from low to high grade. Although the role of p53 in CHS
pathobiology remains obscure, the presence of overexpres-
sionofthep53protein,17p1alterations,andTP53mutations
mainly in almost all high-grade CHSs suggest that the
p53 mutation is a late event involved in CHS progression
[17, 19, 20]. Ampliﬁcation of 12q13 and loss of 9p21 are
some of the few consistent genetic aberrations found in
conventional CHS. The 12q13 region harbors MDM2, a
negative regulator of p53, and the 9p21 region harbors
two cell cycle regulators, CDKN21/p16/INK4A and INK4A-
p14ARF. The loss of INK4A/p16 expression was shown to be
restricted to high-grade CHS, suggesting the role for CHS
progression [17, 21].
2.6. Prognostic Factors. For the prognosis of CHSs, the
single most important predictor of local recurrence and/or
metastasis is histological grade, although several histological
and clinical parameters such as tumor necrosis, mitotic rate,
type of surgery, and tumor location have been suggested to
be associated with prognosis. Grade 1 tumor has indolent
clinical behavior and no metastatic potential. The ﬁve-year
survival by grade was 89% for patients with grade 1 and
57% for the combined group of patients with grades 2 and 3
tumors. Only high tumor grades (2 and 3) were signiﬁcantly
associated with the probability of metastasis [22, 23].
2.7. Treatment. CHS is considered relatively resistant to
chemotherapy or radiotherapy, and the mainstay of treat-
ment is surgical treatment. Wide, en bloc excision is the
preferred surgical treatment in grade 2 or grade 3 CHS. In
grade 1 CHS conﬁned to the bone, extensive intralesional
curettage followed by local adjuvant treatment and ﬁlling
the cavity with bone graft has promising long-term clinical
results and satisfactory local control [24].
2.8. CHSs in Speciﬁc Anatomic Locations
2.8.1. CHSs of the Hands and Feet
(1)Epidemiology. Thehandsandfeetareraresitesforcentral
CHSs, whereas enchondromas are extraordinarily common
in these sites. The median age of the patients at the time
of diagnosis is 67 years (range, 21–87 years), with a slight
preference for female in contrast with CHSs located in other
sites of the skeleton [25, 26].
(2) Sites of Involvement. Occurrences in the hand are more
commonthaninthefoot,withtheproximalphalanxaﬀected
most often. The ﬁfth digit has the highest incidence of CHS,
and the fourth digit is the least common site in the hands
[27].
(3) Clinical Features and Imaging. Pain (usually without
fracture) is usually present at presentation. The median size
is approximately 3cm (range, 1–8cm). Radiologically, CHSs
are predominantly lucent lesions, sometimes with areas of
punctuate calciﬁcation, with irregular cortical destruction
and extension into surrounding soft tissue.Sarcoma 5
(a) (b)
(c) (d)
Figure 4: (a) Grade 1 CHS with chondroid matrix and low cellularity. Note the soft tissue extension. (b) Grade 2 CHS with increased
cellularity and soft tissue extension. (c) Grade 3 CHS with more increased cellularity and cellular atypia. (d) Pleomorphic tumor cells and
frequent multinucleated cells in grade 3 CHS.
Cellularity
Cellular spindling
Mitosis, necrosis
Chondroid matrix
Myxoid change
Nuclear atypia
Grade 1 Grade 2 Grade 3
Figure 5: Schematic representation illustrating grading system of conventional CHS (not all CHSs follow this scheme).6 Sarcoma
Figure 6: CHS permeating between preexisting bony trabeculae.
Based on the cellularity and nuclear atypia, this lesion corresponds
to grade 2 CHS.
Figure 7: Extensive myxoid change in CHS.
(4) Pathology. The distinction between enchondroma and
CHS is often diﬃcult on histologic examination because
enchondromas of the hands and feet can exhibit increased
cellularity, binucleated cells, and hyperchromasia. Therefore,
the most important histologic features of CHS in these sites
are permeative growth pattern between preexisting bones
and extension to soft tissue or joint space. Other histologic
features suggesting malignancy are the presence of myxoid
change and peripheral spindling of neoplastic chondrocytes.
(5) Prognostic Factors. CHSs of the hands and feet are
typically low-grade CHSs with a propensity to recur, but a
limited tendency to metastasize in contrast to CHSs located
elsewhere and complete excision with margins of normal
tissue is curative in almost all cases [25, 26]. CHSs of the
calcaneus and the talus were more likely to metastasize.
2.8.2. CHSs of the Craniofacial Region
(1)EpidemiologyandSitesofInvolvement. CraniofacialCHSs
account for 2% of all CHSs and have a predilection for
the skull base. The mean age of the patients at the time of
diagnosis is 39 years (range, 10–79 years) (mean, 39 years).
The temporo-occipital junction is the most preferred site in
frequency followed by clivus and sphenoethmoid complex
[28].
(2)ClinicalFeaturesandImaging. Mostpatientspresentwith
symptoms related to the central nervous system. CT and MR
imaging reveal bone destruction and associated soft tissue
masses usually containing punctuate areas of chondroid
mineralization [3].
(3) Pathology. The majority of the tumors are conventional
CHSs of low to intermediate grade.
(4) Prognostic Factors. When the skull base CHS involves the
clivus, distinction from chordoma is important because CHS
has a much better prognosis than chordoma. Chordoma
tends to occur in patients a decade older than do CHSs and
grow much more rapidly. Skull base CHS has an excellent
prognosis, and the 5- and 10-year disease-speciﬁc survival
rates are reported to be both 99%. In contrast, the 5- and
10-year survival rates of chordoma have been reported to be
approximately 51% and 35%, respectively [28].
3.Periosteal(Juxtacortical) CHS
Periosteal CHS is a rare malignant hyaline cartilage tumor
arising from the external surface of bone and has also been
referred to as parosteal CHS.
3.1. Epidemiology and Sites of Involvement. This tumor
accounts for less than 2% of all CHSs and 0.2% of all bone
tumors [29]. The tumor tends to aﬀect younger adults than
conventionalCHSwithpeakincidencesinthethirdtofourth
decade of life. There is a slight male predilection. The most
common site is the metaphyseal region of the long bones,
especially the femur and the humerus.
3.2. Clinical Features and Imaging. The clinical signs and
symptoms are mostly nonspeciﬁc and present with pain
or slowly growing mass. The lesion appears to involve
the cortex with indistinct margins. On radiographs, the
tumor often appears as a radiolucent juxtacortical soft tissue
mass with sharply deﬁned borders containing calciﬁcations
characteristic of cartilage tumors.
3.3. Pathology. The lesion is usually large (mean size, 8.1cm)
and covered by a ﬁbrous pseudocapsule that is continuous
with the underlying pseudocapsule. The mass is usually
round to oval, lobulated, and gritty white with areas of
enchondral ossiﬁcation and scattered calciﬁcation. Whereas
periosteal osteosarcoma is commonly fusiform and shows
less-constant chondroid features [30]. Histological features
are similar to those of conventional CHS that is composed
of solid nodules of hyaline cartilage with variable amount of
myxoid stroma. Nodules of the tumor can invade surround-
ing soft tissues. Almost all periosteal CHS corresponds toSarcoma 7
grade 1 or 2 CHS. By deﬁnition, tumor osteoid should not
be present within the tumor [30].
3.4. Diﬀerential Diagnosis. The diﬀerential diagnosis
includes periosteal osteosarcoma. The peak age of incidence
of periosteal osteosarcoma is 10 years younger than CHS.
The most common anatomic site is the diaphysis or
diaphyseal-metaphyseal area of the proximal tibia, followed
by the femur and humerus. Periosteal osteosarcoma
presents as small radiolucent lesions on the surface, with
formation of spicules of bone perpendicular to the bone
shaft. Histologically, periosteal osteosarcoma is intermediate
grade, predominantly chondroblastic osteogenic sarcoma
[31, 32]. Periosteal chondroma also should be distinguished
from periosteal CHS. Periosteal chondroma is a slow-
growing benign cartilaginous tumor arising within or under
the periosteum. The size of the tumor is usually 1–3cm
in diameter. The peak incidence is in the second and third
decades of life. The most common anatomic site is the
metaphyseal region of long tubular bones. The proximal
humerus is the most common site, followed by the femur
and short tubular bones of the hands and feet. Histologically,
the tumor consists of lobules of hyaline cartilage with foci
of myxoid change. Although periosteal chondroma can be
cellularandshowbinucleatedchondrocytes,penetrationinto
cancellous bone and nuclear anaplasia is not identiﬁed [33].
3.5. Prognostic Factors. The prognosis for patients with peri-
osteal CHS is favorable compared to that of intramedullary
CHS. The overall 5-year metastasis-free survival is approx-
imately 83%. The 5-year metastasis-free survival is less for
patients with grade 2 tumors (50%) than for patients with
grade1tumors(94%).Invasionofthemedullarycavityisnot
f r e q u e n t .M e t a s t a s i si se x c e p t i o n a la n do c c u r sv e r yl a t e[ 34].
Dediﬀerentiation has been rarely reported and is associated
with poor prognosis [35].
4.SecondaryCHS
Secondary CHS is a CHS arising in a benign precursor, either
an osteochondroma or enchondroma. Although secondary
CHS can be either central or peripheral, peripheral lesions
a r em o r ec o m m o n .
4.1. Peripheral Secondary CHSs
4.1.1. Epidemiology. Malignant transformation to peripheral
CHS can be seen in 1% of solitary osteochondroma and
3∼5% of patients with osteochondromatosis (hereditary
multiple exostoses, HME) [36, 37]. HME is an autosomal
dominant skeletal disease characterized by the formation
of multiple cartilage-capped bone tumors growing outward
from the metaphyses of long tubular bones.
4.1.2. Genetics. HME is caused by mutations in either of two
genes: exostosin-1 (EXT1), which is located on chromosome
8q24.11–q24.13, and exostosin-2 (EXT2), which is located
on chromosome 11p11-12. Most of the mutations in these
two genes are inactivating mutations (nonsense, frame shift,
or splice-site mutations), causing premature termination of
the EXT proteins and the loss of protein function [38, 39].
In accordance with Knudson’s two-hit model, both alleles
of EXT seem to need to be inactivated for osteochondroma
formation. Loss of heterozygosity (LOH) of EXT1 and/or
EXT2isshowninsomesolitaryosteochondromasandHMEs
(Figures 8(a) and 8(b))[ 40, 41]. The absence of LOH
in a proportion of osteochondromas seems to be because
cartilaginous cap of osteochondroma is mosaic. Therefore,
detection of a second mutational event depends on the
balance between EXT mutated and wild-type cells [42, 43].
In the growth plate, IHH regulates chondrocyte prolif-
eration and diﬀerentiation in a tightly regulated paracrine
feedback loop, together with PTHLH, and deregulated IHH
signaling has been implicated in the pathogenesis of osteo-
chondromas. The EXT genes encode glycosyltransferases
involved in the biosynthesis of heparan sulfate (HS) chains
at HS proteoglycans (HSPGs). HSPGs have been shown
to play a role in the diﬀusion of IHH, PTHLH, and
ﬁbroblast growth factor (FGF), all of which are involved
in chondrocyte proliferation and diﬀerentiation. Therefore,
EXT inactivation aﬀects hedgehog signaling by defective HS
(Figures 8(a) and 8(b)). In addition, disturbed hedgehog
signaling can cause defect in the body collar because
hedgehog is important for the formation of the bony
collar. EXT
−/− cells lose their ability to respond to polarity
signals, then grow out of the bone, and then recruit normal
cells to form an osteochondroma. IHH/PTHLH and FGF
signaling molecules are mostly absent in osteochondromas
and reexpressed with the progression of osteochondroma
towardsperipheralCHSs.UpregulationofPTHLHandBcl-2
characterizes malignant transformation of osteochondroma
[42, 44–46].
4.1.3. Clinical Features and Imaging. In osteochondromas,
lesions that continue to grow or cause pain after skeletal
maturity suggest malignant transformation since osteochon-
dromas only rarely grow after skeletal maturation. A thick
hyaline cartilage cap greater than 1.5∼2.0cm thick (in
osteochondroma: 6 to 8mm thick) in a skeletally mature
patient has been cited as a sign of possible malignant
transformation(Figure 9).However,thekeyforthediagnosis
is the histopathologic diﬀerentiation of the cartilaginous
proliferation. Radiographic ﬁndings that suggest malignancy
are growth of a previously unchanged osteochondroma in
a skeletally mature patient, irregular or indistinct lesional
surface, focal regions of radiolucency in the interior of the
lesion, erosion or destruction of the adjacent bone, and a
soft tissue mass with scattered or irregular calciﬁcations.
Malignant transformation develops earlier in patients with
HME (average, 25∼30 years) than in those with solitary
osteochondroma (average, 50∼55 years). Malignant trans-
formation before the age of 20 is very unusual [37, 47].
4.1.4. Pathology. CHS arising in osteochondroma is usu-
ally solitary and low grade in type, but multifocality
and dediﬀerentiation have also been reported (Figure 10).8 Sarcoma
Chondrocyte
diﬀerentiation EXT
HSPG FGF-FGFR +
+
Diﬀusion of IHH
Patched-IHH
5. Ossiﬁcation
3. Transition zone
2. Proliferating zone
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IHH
Bcl-2
1. Resting chondrocytes
PTHLH 4. Hypertrophic
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(a)
Peripheral secondary CHS, low grade
Growth plate chondrocytes
HME Sporadic OC
Germline mutation of
EXT1 or EXT2
L O Ho fE X T 1
and/or EXT2
Genetic instability
Reactivation of PTHLH
signaling
Homozygous EXT1
deletions
(b)
Growth plate chondrocytes
PTHR1 mutation
Enchondromatosis Enchondroma
?
Active PTHLH signaling
Inactive hedgehog signaling
Central secondary CHS, low grade
(c)
Figure 8: (a) Schematic representations of IHH/PTHLH signaling in the growth plate. The growth plate is composed of chondrocytes at
diﬀe r e n ts t a g e so fd i ﬀerentiation, ﬁnally leading to longitudinal bone growth. This process is tightly regulated by IHH/PTHLH signaling.
IHH, expressed by transition zone chondrocytes, diﬀuses and binds to Patched (Ptc) in the hypertrophic zone, stimulating PTHLH
expression. PTHLH then binds to its receptor in the transition zone and upregulates Bcl-2, which inhibits chondrocyte diﬀerentiation and
downregulates IHH secretion. EXT gene products play a role in the diﬀusion of hedgehog proteins and FGF-FGFR interaction. Therefore,
defect or absence of EXT genes results in an abnormal IHH diﬀusion pattern, leading to an osteochondroma. (b) Proposed genetic model
for peripheral secondary CHS. Analogous to Knudson’s two-hit model, both alleles of an EXT gene are inactivated for osteochondroma
formation in both HME and solitary osteochondroma. Genetic instability and reactivation of PTHLH signaling characterizes the malignant
transformation of osteochondroma. (c) Proposed genetic model for central secondary CHS. Patients with enchondromatosis infrequently
harbor PTHR1 mutation, which disrupts the normal IHH-PTHLH feedback loop, leading to constitutive hedgehog signaling. In most
enchondromas, causative genetic or epigenetic changes have not been identiﬁed.Sarcoma 9
Figure 9: Secondary CHS arising in osteochondroma. Note the
thickening of cartilage cap (2.5cm, arrows).
On microscopic examination, loss of cartilaginous colum-
nar architecture, ﬁbrous bands between cartilage lobules,
increased nuclear atypia, mitosis, or myxoid changes are
features suggestive of malignant transformation.
4.1.5. Prognostic Factors and Treatment. Malignant transfor-
mation of osteochondroma is usually treated with surgery.
Treatment of patients with HME is more complex than that
of patients with solitary osteochondroma. Because most of
these lesions are low-grade CHS, the overall prognosis is
good, with long-term survival in 70∼90% of patients. Local
recurrence rate varies with adequacy of the tumor margins,
from0–15%inwidelyresectedcasesto57∼78%incaseswith
marginal or intralesional resection [37, 48]
4.2. Central Secondary CHSs
4.2.1. Epidemiology. Central secondary CHSs develop as
malignant transformation of enchondroma (extremely rare)
or enchondromatosis such as Ollier disease or Maﬀucci syn-
drome. Patients with Ollier disease and Maﬀucci syndrome
have a 25∼30% risk of developing CHS.
4.2.2. Genetics. The exact cause of Ollier disease and Maf-
fucci syndrome remains to be elucidated, although mutation
inthePTHR1gene,c.448C>T(p.R150C),hasbeensuggested
to cause enchondromatosis [49, 50] .Am u t a t i o ni nP T H R 1
disrupts the normal IHH-PTHLH feedback loop, causing
constitutive hedgehog signaling (Figure 8(c)).
4.2.3. Clinical Features and Imaging. Ollier disease is a
nonhereditary developmental abnormality characterized by
multiple enchondromas throughout the epiphyses, meta-
physes, and diaphyses of the skeleton. The size, number,
location, and evolution of enchondromas are quite variable.
Clinically, Ollier disease often shows asymmetric, unilateral
involvement of the lower extremities, but it is often bilateral
in the hands and feet. Any portion of the skeleton formed
by endochondral ossiﬁcation can be aﬀected; however,
Ollier disease rarely aﬀects bones formed by membranous
Figure 10: Grade 1 CHS arising in osteochondroma with loss of
organized architecture and mild nuclear atypia.
ossiﬁcation, such as the skull and facial bones. Maﬀucci
syndrome is a condition in which enchondromatosis is
associated with soft tissue hemangiomas [51, 52].
The development of pain as well as the appearance of soft
tissue mass, areas of bone destruction, endosteal scalloping,
periosteal reaction, and fracture without signiﬁcant trauma
raises the suspicion of malignant transformation of enchon-
dromatosis.
4.2.4. Pathology. CHS arising in enchondromatosis is usually
a low-grade tumor like that of osteochondroma or HME.
Therefore, identiﬁcation of invasion to surrounding tissues
or marked myxoid change is helpful to the diagnosis.
4.2.5. Prognostic Factors and Treatment. CHS in enchondro-
matosis has the same prognosis as conventional CHS and
depends on the site and grade of the tumor. Malignant
transformation of enchondromatosis is greater in Maﬀucci
syndrome than Ollier disease, and the prognosis is worse
than that of Ollier disease.
5. Dedifferentiated CHS
Dediﬀerentiated CHS is a distinct variant of CHS containing
a well-diﬀerentiated cartilage tumor, either an enchondroma
or a low-grade CHS, with an abrupt transition to foci having
high-grade noncartilaginous sarcoma (Figures 11(a)–11(c)).
5.1. Epidemiology and Sites of Involvement. Dediﬀerentiated
CHSmakesup10%ofCHSs.Theaverageageofpresentation
is between 50 and 60 years. Men and women are aﬀected
equally. The most common aﬀected sites are the femur and
pelvis [53, 54]. The majority of lesions occur centrally in
the medullary cavity of bone, although there are reports of
dediﬀerentiation in juxtacortical CHS or from preexisting
osteochondroma [35, 55].
5.2.ClinicalFeaturesandImaging. Thepatientspresentmost
frequently with pain (90%), followed by pathologic fracture10 Sarcoma
(a)
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Figure 11: (a) An ill-demarcated lobulating ﬁrm mass (8.5 × 4.0
× 4.0cm) in the proximal femur. Most of the mass which is white
to bluish gray is conventional chondrosarcoma. The yellowish
gray area in the center (arrows) is dediﬀerentiated area. (b) The
abrupt transition between conventional CHS and dediﬀerentiated
component. (c) The dediﬀerentiated component consisting of
malignant spindle cells without matrix formation (malignant
ﬁbrous histiocytoma).
and soft tissue mass. The proportion of noncartilaginous
component varies greatly and may be frequently osteosar-
coma, ﬁbrosarcoma, or malignant ﬁbrous histiocytoma.
Rhabdomyosarcoma, leiomyosarcoma, and angiosarcoma
have been reported as the dediﬀerentiated component.
Dediﬀerentiated CHSs have a wide range of radiological
appearance; however, the presence of “tumoral dimorphism”
with cartilaginous component and aggressive lytic compo-
nent invading adjacent soft tissues suggests a diagnosis of
dediﬀerentiated CHS [56].
5.3. Histogenesis. There are at least three hypotheses explain-
ing the origin of dediﬀerentiated CHS. One theory is that
the high-grade noncartilaginous tumor component arises in
a long-standing low-grade cartilaginous tumor, particularly
when the tumor is recurrent. The second hypothesis is
that noncartilaginous component arises simultaneously with
CHS with ability to diﬀerentiate. The third theory is that
noncartilaginous sarcoma represents malignant transforma-
tion of adjacent inﬂamed but otherwise normal tissue [53].
5.4. Genetics. So far, no speciﬁc aberrations seem to be
associated with dediﬀerentiated CHS, although dediﬀer-
entiated component tends to show aneuploidy, loss of
heterozygosity, and ampliﬁcation and deletion more fre-
quently [57]. Recently an array-based comparative genomic
hybridization (Array-CGH) study demonstrated statistically
signiﬁcant association between high-grade tumor (grade III
and dediﬀerentiated) and the recurrent genetic deletions at
5q14.2∼q21.3, 6q16∼q25.3, 9p24.2∼q12, and 9p21.3 [58].
RegardingdediﬀerentiatedperipheralCHSs,dediﬀerentiated
component shows more frequent expression of cyclin D1,
p53, plasminogen activator inhibitor 1 (PAI-1), and CD44.
The PTHLH signaling seems to be downregulated in chon-
drogenic component of dediﬀerentiated peripheral CHSs
whereas FGF signaling pathway in active, compared with
secondary peripheral CHSs without dediﬀerentiation [59].
5.5. Prognostic Factors. Because the dediﬀerentiated compo-
nent determines the prognosis, its identiﬁcation is a key for
management. In spite of aggressive treatment, the overall
survival rate is less than 10% at ﬁve years, with a median
survival time of 7.5 months. While local control is achieved
in the majority of cases, distant disease remains the greatest
clinical challenge, developing in 90% of patients [60].
6. Mesenchymal CHS
Mesenchymal CHS is a rare highly malignant tumor that
arises in bone but can occur in extraskeletal sites and is
characterized by highly cellular areas composed of undiﬀer-
entiated small round or spindle cells admixed with lobules of
mature hyaline cartilage.
6.1.Epidemiology. MesenchymalCHSmakesuplessthan2∼
1 3 %o fa l lp r i m a r yC H S s .M e s e n c h y m a lC H So c c u r sa ta n y
age, with peak incidences in the second to third decades of
life. There is no signiﬁcant sex predilection [61].
6.2. Sites of Involvement. The skeletal tumors show a wide-
spread distribution. The craniofacial region is the most
frequently aﬀected site (15∼30%), speciﬁcally the mandible
and maxilla. Other common sites include femur, ribs, spine,
pelvis, and humerus [1, 3]. About 7% of the osseous lesions
are reported to be multicentric. Up to one-third of theSarcoma 11
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Figure 12: (a) Mesenchymal CHS showing bimorphic pattern,
consisting of islands of hyaline cartilage and undiﬀerentiated
cells. Note hemangiopericytomatous vascular pattern. (b) The
undiﬀerentiated small cells with relatively uniform oval to round
nuclei and scanty amount of cytoplasm.
lesions primarily aﬀect extraskeletal sites. The meninges
(cranial > spinal) are the most common sites of extraskeletal
involvement, followed by lower extremity [61].
6.3. Clinical Features and Imaging. Most patients presented
with pain and/or swelling. Duration of symptoms prior to
the histologic diagnosis is quite variable, ranging from few
days to several years. Oncogenic osteomalacia secondary to
mesenchymal CHS has been reported.
Roentgenographically, mesenchymal CHSs in bone fre-
quently resemble ordinary CHSs, showing osteolytic and
destructive appearances with stippled calciﬁcations. Tumors
in extraskeletal sites are almost always identiﬁed as a mass
with ﬂocculent or stippled calciﬁc densities. Sclerosis or
periosteal reaction is uncommon, while expansion of the
bone, cortical destruction, or cortical breakthrough with
extraosseous extension of soft tissue is common [61].
6.4. Pathology
6.4.1. Gross Findings. Grossly, the tumors are gray to tan,
ﬁrm to soft, and usually well deﬁned and well circumscribed.
The size of the tumor ranges from 3cm to 30cm in diameter.
Figure 13:Theundiﬀerentiatedsmallcellcomponentinmesenchy-
mal CHS strongly positive for CD99.
Lobulation is infrequent. Most lesions contain hard miner-
alized deposits that vary in amount from scattered foci to
prominent areas. Some tumors show a clearly cartilaginous
appearance, even in a small area. Necrosis is uncommon but
may be prominent [62]. Bony expansion with cortical thin-
ning or bone destruction and soft tissue invasion is frequent.
6.4.2. Microscopic Findings. Histologically, a bimorphic pat-
tern with cellular zones of undiﬀerentiated small or spindle
cells and islands of hyaline cartilage is pathognomonic
(Figure 12). The amount of cartilage is highly variable.
Transition from cellular areas to zones with hyaline cartilage
is usually abrupt but can be gradual. The undiﬀerentiated
c e l l sw i t ho v a ln u c l e if r e q u e n t l yt e n dt ob ea r r a n g e di na
vague alveolar pattern or in solid sheets, resembling Ewing
sarcoma.Ahemangiopericytomatousvascularpatternisseen
in most cases. Osteoclastic giant cells can be seen, usually
adjacent to the cartilaginous islands [61].
6.4.3. Immunohistochemical Findings. Immunohistochemi-
cally, the cartilaginous area is strongly positive for S-100
protein, whereas only scattered single cells in the undiﬀer-
entiated areas stain for this antigen. The undiﬀerentiated
small cell component of mesenchymal CHSs is consistently
positiveforCD99andmaystainforvimentinandLeu7while
negative for osteocalcin, actin, cytokeratin, and epithelial
membrane antigen (EMA) (Figure 13). SOX9 is almost
invariably positive in both components [63, 64].
6.5. Genetics. At present, cytogenetic ﬁndings of mes-
enchymal CHS are rarely reported. An identical Robert-
sonian translocation involving chromosomes 13 and 21
(der(13;21)(q10;q10)) has been detected in two cases of
mesenchymal CHSs, possibly representing a characteristic
rearrangement for this histopathologic entity [65]. The
t(11;22) of the Ewing family of tumors is not seen in
mesenchymal CHS. Although approximately 60% of the
tumors demonstrate p53 overexpression, no mutation has
been found within exons 5∼9 regions [66].12 Sarcoma
Figure 14: Clear cell CHS located in the epiphysis metaphysis of
the proximal femur. The lesion is lytic, slightly expansile, and well
delineated from the adjacent normal bone.
6.6. Prognostic Factors. The prognosis of mesenchymal CHS
is poor. However, the clinical course may be protracted.
Because local recurrence or metastasis sometimes is encoun-
tered even after more than 20 years, long-term follow-up is
essential. The 5-year survival rate was 54.6%, and the 10-
year survival rate was 27.3% in a group of 23 patients from
the Mayo Clinic. The most frequent site of metastasis is the
lung. Ablative surgical treatment seems to be the treatment
of choice [61].
7.ClearCellCHS
Clear cell CHS is a rare, low-grade malignant tumor
characterized by clear cytoplasm of the tumor cells.
7.1. Epidemiology and Sites of Involvement. The tumor
accounts for about 1-2% of all CHSs. The lesion aﬀects
males more commonly than females (2.6:1) and has a
predilection for the end of long bones (epiphysis) in contrast
to conventional CHS which tends to occur in the meta-
diaphysealregions ofthe bone. Although the proximal femur
and humeral head are the sites most commonly aﬀected in
about two-thirds of the cases by this lesion, most bones
including spine, rib, pelvis, and hands and feet can be
involved. The age range is wide with peak incidences in the
third to fourth decades of life [67].
7.2. Clinical Features and Imaging. Clinically, clear cell CHS
presentsoneortwodecadeslaterthanchondroblastoma.The
clinical symptoms are nonspeciﬁc; however, pain is the most
common presenting symptom. More than half of patients
have pain for longer than a year.
Figure 15: Gross ﬁnding of clear cell chondrosarcoma in the
proximal femur.
Roentgenographically, the lesion is typically located in
the epiphysis metaphysis of long bone. The lesion is most
often purely lytic and slightly expansile, with a sharp
margin between the tumor and the adjacent normal bone
(Figure 14). Typically, there is no cortical destruction or
periosteal new bone formation. More than one-third of the
long bone lesions contained matrix mineralization with a
characteristic chondroid appearance. Pathologic fracture is
occasionally present. Flat bone lesions are typically lytic and
expansile with occasionally demonstrated areas of cortical
disruption.Typically,matrixmineralization,whenpresent,is
amorphous.Adjacentbonemarrowedemaistypicallyabsent
or only minimally observed [68].
7.3. Pathology. Grossly, the tumors are well circumscribed
andmaybeeitherﬁrmorsoft.Grosslycartilageisnotusually
present(Figure 15).Thelesionsconsistofclearcellsarranged
in an indistinct lobular pattern and having round, large,
centrally located nuclei with clear cytoplasm and distinct
cytoplasmic membranes (Figure 16). Clear cell components
in clear cell CHS are accompanied by “conventional” foci
of CHS in less than 50% of cases. Secondary ﬁndings
including areas of osteogenesis, osteoclast-like giant cells,
and zones resembling aneurysmal bone cyst or giant cell
tumor of bone could be found. Mitotic ﬁgures are rare
[69]. Dediﬀerentiation to high-grade sarcoma has been
rarely reported [70]. Clear cell CHS should be diﬀerentiated
from other osseous tumors which can show focal or diﬀuse
clear cell changes such as osteosarcoma, chondroblastoma,
chordoma, adamantinoma, and Ewing’s sarcoma/primitive
neuroectodermal tumor as well as metastatic renal clear cell
carcinoma. The clear cells are positive for type II collagen as
well as S-100 protein and aggrecan [71].
7.4. Genetics. Recent molecular genetic studies show that
genetic alterations of p53 are infrequent in clear cell CHS
in spite of substantial overexpression of p53 [72]. Tumor-
speciﬁc cytogenetic change is currently unknown; although
a case report described clonal chromosomal abnormalities in
three of four cases of clear cell CHS [73].Sarcoma 13
(a)
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Figure 16: (a) Tumor cells with clear cytoplasm between irregular
trabeculae of woven bone. (b) Higher magniﬁcation of tumor cells
withabundantclearorfaintlygranularcytoplasmandcentralround
nuclei containing occasional prominent nucleoli.
7.5. Prognostic Factors. Clear cell CHS is a low-grade malig-
nancyandusuallycurablebyenblocresection.About25%of
patientsexperiencelocalrecurrencesormetastases.However,
tumor-related death is uncommon, particularly when the
lesion has been completely resected en bloc [69].
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